+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Endometriosis Treatment Market - Global Forecast 2026-2032- Product Image
Endometriosis Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Endometriosis Treatment Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4989704
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Endometriosis Treatment Market is projected to reach USD 1.64 Billion in 2026. It is expected to continue growing at a CAGR of 8.06%, reaching USD 2.62 Billion by 2032.

Endometriosis treatment is moving from symptom control toward earlier diagnosis, long-term disease management, and fertility-aware care pathways. The condition affects about 10% of reproductive-age women and girls worldwide, or roughly 190 million people, according to the World Health Organization, making it a high-burden gynecological disease with substantial implications for chronic pelvic pain, productivity, mental health, sexual health, and reproductive outcomes.

Demand for endometriosis drugs, minimally invasive surgery, diagnostics, and multidisciplinary care is reinforced by historically delayed diagnosis, recurrent symptoms, and the need to balance efficacy with safety. Industry participants are prioritizing non-opioid pain management, combined hormonal contraceptives, progestins, GnRH agonists and oral GnRH antagonists with add-back therapy, imaging-enabled diagnosis, and patient-centered care models that reduce time to appropriate treatment.

Transformative Shifts in the Endometriosis Treatment Landscape

The endometriosis treatment landscape is being reshaped by a shift away from repeated empirical treatment toward evidence-based, individualized care. Updated clinical guidance from organizations such as ESHRE and NICE emphasizes shared decision-making, symptom severity, fertility goals, adverse-effect profiles, recurrence prevention, and long-term follow-up rather than a one-size-fits-all pathway.

Transformative change is also visible in pharmacotherapy and surgical practice. Oral GnRH antagonists have expanded options beyond injectable suppression approaches, while laparoscopy continues to support lesion removal and diagnosis in appropriate patients, particularly for deep infiltrating disease, endometriomas, or infertility-related evaluation. At the same time, specialist ultrasound, MRI, multidisciplinary pelvic pain clinics, fertility-preservation counseling, and digital symptom tracking are improving continuity of care and strengthening treatment adherence.

Cumulative Impact of Artificial Intelligence on Endometriosis Care

Artificial intelligence is beginning to influence endometriosis care across diagnosis, trial design, treatment planning, and patient monitoring. AI-enabled analysis of ultrasound and MRI images may support more consistent identification of deep infiltrating endometriosis and ovarian endometriomas, while natural language processing can help identify patients with recurring pelvic pain, dysmenorrhea, dyspareunia, infertility, and gastrointestinal or urinary symptom patterns in electronic health records.

The cumulative impact of AI is most significant when it reduces diagnostic delay and improves treatment matching. Predictive models can support risk stratification, real-world evidence generation, clinical trial recruitment, and longitudinal monitoring of patient-reported outcomes. However, adoption depends on clinically validated algorithms, representative datasets, transparent performance reporting, clinician oversight, interoperability with care systems, and compliance with medical device, privacy, cybersecurity, and health equity requirements.

Key Regional Insights Across Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is emerging as a major development arena for endometriosis treatment due to large reproductive-age populations, improving access to gynecologic care, rising diagnosis of chronic pelvic pain, and increasing awareness in China, India, Japan, South Korea, and Australia. Japan and Australia have mature diagnostic and surgical ecosystems with strong use of minimally invasive gynecology and imaging, while China and India present high-volume opportunities as urban hospital networks, fertility services, and women’s health investments expand. In parts of Southeast Asia, access continues to vary between metropolitan specialist centers and underserved rural areas, reinforcing the need for affordable diagnostics, clinician training, and referral pathway development.

North America remains a leading endometriosis treatment region supported by specialist access, advanced minimally invasive surgery, approved hormonal therapies, clinical research activity, and active patient advocacy. Europe benefits from structured clinical guidelines and reimbursement pathways, particularly across Germany, France, Italy, Spain, and the United Kingdom, with growing emphasis on multidisciplinary endometriosis centers and standardized imaging. Latin America is seeing rising demand in Brazil, Mexico, and other urban healthcare hubs as private care and fertility treatment expand, although affordability and uneven specialist distribution remain constraints. The Middle East is supported by expanding hospital infrastructure and demand for fertility and advanced gynecology services, particularly in higher-income health systems, while Africa faces significant underdiagnosis, specialist shortages, and access barriers that create a strong need for awareness, training, and scalable care models.

Key Group Insights for ASEAN, GCC, European Union, BRICS, G7, and NATO Markets

ASEAN countries are strengthening women’s health infrastructure, although endometriosis diagnosis often remains concentrated in urban tertiary centers and private hospitals, making referral networks and clinician education essential for earlier care. GCC markets benefit from high healthcare spending, expanding private hospital capacity, medical tourism ambitions, and demand for advanced fertility and minimally invasive gynecology services, supporting adoption of premium diagnostics, surgical techniques, and specialist-led treatment pathways.

The European Union provides a favorable environment for harmonized clinical standards, pharmacovigilance, post-market surveillance, and cross-border research collaboration, while national reimbursement and health technology assessment processes continue to shape access to therapies and procedures. BRICS countries represent scale and unmet clinical need, led by China, India, and Brazil, with Russia and South Africa reflecting more variable access conditions. G7 markets drive innovation through established regulatory systems, academic research, specialty care networks, and access to advanced pharmaceutical and surgical options. NATO countries overlap with several advanced healthcare markets where supply resilience, data governance, cybersecurity, and medical technology security increasingly influence healthcare strategy for digitally enabled endometriosis care.

Key Country Insights in Major Endometriosis Treatment Markets

The United States leads in branded therapy availability, clinical trials, patient advocacy, specialty pelvic pain care, and advanced laparoscopic treatment, while Canada emphasizes publicly funded care pathways, provincial access planning, and equitable specialist referral across geographically dispersed populations. Mexico and Brazil show rising demand as private healthcare, fertility services, gynecologic imaging, and minimally invasive surgery expand, though out-of-pocket costs, insurance coverage variation, and specialist concentration remain important barriers to consistent treatment access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are guided by strong clinical networks, reimbursement frameworks, specialist gynecology expertise, and growing awareness campaigns focused on reducing diagnostic delay. Germany and France benefit from advanced hospital infrastructure and structured care pathways, while the United Kingdom continues to emphasize guideline-led management and recognition of endometriosis as a long-term condition. Italy and Spain show strong surgical and reproductive medicine capabilities, and Russia presents demand for gynecologic care but faces system and access variability. China and India offer significant long-term development potential due to population scale, healthcare modernization, expanding women’s health services, and rising fertility care demand. Japan, Australia, and South Korea combine high diagnostic capability with advanced minimally invasive surgery, specialist imaging, and women’s health innovation, supporting evidence-based adoption of new endometriosis treatment approaches.

Actionable Recommendations for Endometriosis Treatment Industry Leaders

Industry leaders should prioritize solutions that shorten diagnostic delay, improve symptom control, reduce recurrence burden, and preserve fertility choices. This includes investment in validated noninvasive diagnostics, specialist imaging protocols, patient-reported outcome tools, AI-assisted clinical decision support, and therapies with clear safety, tolerability, bone-health, adherence, and quality-of-life advantages.

Commercial strategy should align with local reimbursement realities, treatment guidelines, and clinician education needs. Organizations can gain advantage by partnering with gynecologists, radiologists, fertility specialists, pain experts, primary care clinicians, payers, and patient advocacy groups to build integrated care pathways. Real-world evidence, health economics data, inclusive clinical trials, and region-specific access programs should be used to demonstrate value across diverse patient populations without relying on unsupported market claims.

Research Methodology for Endometriosis Treatment Analysis

This executive summary is developed using a secondary research methodology grounded in authoritative public sources, including WHO disease burden information, clinical guidance from ESHRE and NICE, regulatory information from FDA and EMA resources, peer-reviewed gynecology literature, systematic reviews, public health publications, and publicly available healthcare system disclosures.

Insights are synthesized through treatment pathway assessment, regional healthcare access analysis, technology adoption review, regulatory and reimbursement scanning, and evaluation of clinical practice trends. The methodology emphasizes verified evidence, triangulation across credible sources, and exclusion of unsupported market sizing, market share, and forecasting claims to ensure accuracy, relevance, and SEO-ready industry positioning for endometriosis treatment analysis.

Conclusion: Advancing Evidence-Based Endometriosis Treatment

Endometriosis treatment is entering a more patient-centered and technology-enabled phase, driven by unmet diagnostic needs, the burden of chronic pelvic pain, infertility concerns, and growing demand for fertility-conscious care. The sector is supported by expanding therapeutic options, improved minimally invasive surgical practice, stronger imaging capability, multidisciplinary care, and greater awareness of the disease’s social and economic impact.

Future leadership will depend on evidence-based innovation, equitable access, and integrated care delivery. Organizations that combine validated diagnostics, effective therapies, real-world data, clinician education, and regional adaptation will be best positioned to improve outcomes and support sustainable progress in the global endometriosis treatment landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Endometriosis Treatment Market, by Treatment Type
7.1. Introduction
7.2. Complementary Therapies
7.3. Hormonal Therapies
7.3.1. Aromatase Inhibitors
7.3.2. Gnrh Agonists
7.3.3. Gnrh Antagonists
7.3.4. Oral Contraceptives
7.3.5. Progestins
7.4. Pain Management
7.4.1. Nsaids
7.4.1.1. Diclofenac
7.4.1.2. Ibuprofen
7.4.1.3. Naproxen
7.4.2. Opioids
7.4.2.1. Codeine
7.4.2.2. Morphine
7.5. Surgical Treatment
8. Endometriosis Treatment Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
8.4. Topical
9. Endometriosis Treatment Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals
9.4. Specialty Clinics
10. Endometriosis Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Endometriosis Treatment Market, by Region
11.1. Asia-Pacific
11.2. Europe
11.3. North America
11.4. Latin America
11.5. Africa
11.6. Middle East
12. Endometriosis Treatment Market, by Group
12.1. NATO
12.2. G7
12.3. BRICS
12.4. European Union
12.5. ASEAN
12.6. GCC
13. Endometriosis Treatment Market, by Country
13.1. China
13.2. United States
13.3. Japan
13.4. India
13.5. Germany
13.6. United Kingdom
13.7. Australia
13.8. France
13.9. South Korea
13.10. Italy
13.11. Canada
13.12. Russia
13.13. Brazil
13.14. Mexico
13.15. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. Amneal Pharmaceuticals Inc.
15.3. Anika Therapeutics, Inc.
15.4. Astellas Pharma Inc.
15.5. AstraZeneca plc
15.6. Bayer AG
15.7. Eli Lilly and Company
15.8. Ferring International Center S.A.
15.9. Gedeon Richter Plc
15.10. Johnson & Johnson Services, Inc.
15.11. Kissei Pharmaceutical Co., Ltd.
15.12. Livzon Pharmaceutical Group Inc.
15.13. Merck & Co., Inc.
15.14. Myovant Sciences Ltd.
15.15. Neurocrine Biosciences, Inc.
15.16. Novartis AG
15.17. ObsEva SA
15.18. Pfizer Inc.
15.19. Repros Therapeutics Inc.
15.20. Sanofi S.A.
15.21. Shionogi & Co., Ltd.
15.22. Takeda Pharmaceutical Company Limited
15.23. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL COMPLEMENTARY THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL COMPLEMENTARY THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL COMPLEMENTARY THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL AROMATASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL AROMATASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL AROMATASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL GNRH AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL GNRH AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL GNRH AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ORAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ORAL CONTRACEPTIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ORAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PROGESTINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PROGESTINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PROGESTINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL NSAIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL NSAIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL NSAIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL DICLOFENAC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL DICLOFENAC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL DICLOFENAC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL IBUPROFEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL IBUPROFEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL IBUPROFEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL NAPROXEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL NAPROXEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL NAPROXEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CODEINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL MORPHINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL MORPHINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL MORPHINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 92. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 94. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 95. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 96. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 97. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 98. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 99. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 100. EUROPE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 119. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 121. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 122. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 123. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 124. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 125. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 126. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 127. AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 140. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 141. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 142. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 143. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 144. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 145. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. NATO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 147. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 149. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 150. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 151. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 152. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 153. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 154. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. G7 ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 158. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 159. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 160. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 161. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 162. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 163. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 164. BRICS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 174. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 175. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 176. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 177. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 178. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 179. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 180. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. ASEAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 183. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 184. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 185. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 186. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 187. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 188. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 189. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 190. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. GCC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 192. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 193. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 194. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 195. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 196. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 197. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 198. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 199. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 200. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 211. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 212. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 213. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 214. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 215. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 216. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 217. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 220. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 221. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 222. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 223. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 224. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 225. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 226. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 229. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 230. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 231. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 232. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 233. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 234. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 235. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 236. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 237. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 238. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 240. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 241. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 242. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 247. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 249. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 250. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 251. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 252. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 253. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 254. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 256. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 258. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 259. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 260. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 261. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 262. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 267. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 268. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 269. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 270. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 271. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 272. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 274. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 275. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 276. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 277. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 278. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 279. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 280. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 281. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 283. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 284. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 285. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 286. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 287. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 288. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 289. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 290. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 291. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 292. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 293. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 294. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 295. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 296. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 297. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 298. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 299. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 302. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 303. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 304. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 305. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 306. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 307. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 308. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 310. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 311. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 312. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 313. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 314. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 315. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 316. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 317. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 318. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 319. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 321. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 322. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, 2017-2032 (USD MILLION)
TABLE 323. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, 2017-2032 (USD MILLION)
TABLE 324. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY OPIOIDS, 2017-2032 (USD MILLION)
TABLE 325. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 326. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 327. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 328. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 329. GLOBAL ENDOMETRIOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Anika Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Eli Lilly and Company
  • Ferring International Center S.A.
  • Gedeon Richter Plc
  • Johnson & Johnson Services, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Merck & Co., Inc.
  • Myovant Sciences Ltd.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • ObsEva SA
  • Pfizer Inc.
  • Repros Therapeutics Inc.
  • Sanofi S.A.
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.64 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.62 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Endometriosis Drugs Market - Global Forecast 2026-2032 - Product Image

Endometriosis Drugs Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Endometriosis Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035) - Product Image

Endometriosis Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

  • Report
  • 400 Pages
  • Global
From
Endometriosis Market Report by Type, Diagnosis and Treatment, End Users, and Region 2026-2034 - Product Image

Endometriosis Market Report by Type, Diagnosis and Treatment, End Users, and Region 2026-2034

  • Report
  • 150 Pages
  • Global
From
Endometriosis Treatment Market Size, Share & Trends Analysis Report by Treatment Type, Drug Class, Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2026-2033 - Product Image

Endometriosis Treatment Market Size, Share & Trends Analysis Report by Treatment Type, Drug Class, Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2026-2033

  • Report
  • 110 Pages
  • Global
From
Endometriosis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Endometriosis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 110 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.